On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

Looking for the latest stock opportunities in December 2024? We have you covered. Click to read our top stock picks to ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...

Get-Up 3 will feature Brittany Howard of Alabama Shakes, Mike Cooley of Drive-by Truckers, Lee Bains and more.

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

Julian Harrison gave his rating based on several factors surrounding Protagonist Therapeutics’ promising drug candidate, JNJ-2113. The upcoming Phase 3 trial data for JNJ-2113 in psoriasis is pivotal, ...